- Home
- MCI vs CDXS Comparison
MCI vs CDXS Comparison
Compare MCI & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCI
- CDXS
- Stock Information
- Founded
- MCI 1971
- CDXS 2002
- Country
- MCI United States
- CDXS United States
- Employees
- MCI N/A
- CDXS N/A
- Industry
- MCI Trusts Except Educational Religious and Charitable
- CDXS Major Chemicals
- Sector
- MCI Finance
- CDXS Industrials
- Exchange
- MCI Nasdaq
- CDXS Nasdaq
- Market Cap
- MCI 400.8M
- CDXS 361.3M
- IPO Year
- MCI N/A
- CDXS 2010
- Fundamental
- Price
- MCI $23.25
- CDXS $4.18
- Analyst Decision
- MCI
- CDXS Buy
- Analyst Count
- MCI 0
- CDXS 2
- Target Price
- MCI N/A
- CDXS $11.00
- AVG Volume (30 Days)
- MCI 40.4K
- CDXS 566.1K
- Earning Date
- MCI 01-01-0001
- CDXS 02-27-2025
- Dividend Yield
- MCI 8.46%
- CDXS N/A
- EPS Growth
- MCI N/A
- CDXS N/A
- EPS
- MCI 1.82
- CDXS N/A
- Revenue
- MCI N/A
- CDXS $64,446,000.00
- Revenue This Year
- MCI N/A
- CDXS N/A
- Revenue Next Year
- MCI N/A
- CDXS $2.02
- P/E Ratio
- MCI $9.88
- CDXS N/A
- Revenue Growth
- MCI N/A
- CDXS N/A
- 52 Week Low
- MCI $12.96
- CDXS $2.56
- 52 Week High
- MCI $19.24
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- MCI 62.89
- CDXS 41.30
- Support Level
- MCI $21.00
- CDXS $4.14
- Resistance Level
- MCI $21.33
- CDXS $4.41
- Average True Range (ATR)
- MCI 0.79
- CDXS 0.22
- MACD
- MCI 0.29
- CDXS 0.01
- Stochastic Oscillator
- MCI 57.11
- CDXS 38.89
About MCI Barings Corporate Investors
Barings Corporate Investors is a closed-end management investment company. Its investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. The Trust's principal investments are privately placed, below-investment grade, long-term debt obligations including bank loans and mezzanine debt instruments. These investments are typically made to small or middle market companies. The company invests in various sectors such as aerospace and defense; automotive; building materials; consumer products and others.
About CDXS Codexis Inc.
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.